You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動|再鼎醫藥一度漲超17%創近兩年新高 去年產品收入淨額同比增加49%
格隆匯 03-28 14:27

再鼎醫藥(9688.HK)盤中一度漲超17%,最高觸及32.5港元,創2023年3月以來新高。

消息面上,再鼎醫藥公佈2024年業績,產品收入淨額同比增加49%至3.976億美元,主要受衛偉迦®自2023年9月上市及於2024年1月被納入國家醫保目錄以來銷售額增加,同時亦得益於則樂®及紐再樂®的銷售額增加所推動。

自2024年第四季度以來,隨着集團於中國內地推出了用於治療gMG及CIDP的衛力迦(艾加莫德的皮下製劑)、用於治療ABC引起的HABP及VABP的鼎優樂以及用於治療ROS1+NSCLC的奧凱樂,集團喜見集團的商業化組合日益壯大。於2025年,集團預期現有及近期上市的商業化產品的收入將繼續增長。(格隆匯)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account